Loading quotes...

Forecast

Buy	1
Hold	0
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Arca Continental increases revenue in Q3 2025 despite macroeconomic challenges

Arca Continental reported a consolidated revenue increase of 0.5% to 62.9 billion pesos in Q3 2025 and a net income rise of 3.5% to 5.3 billion pesos. The EBITDA margin improved to 20.4% and the net profit margin to 8.4%. The company highlights the expansion of low-calorie products, portfolio broadening and market resilience, but warns of continued volatility, possible tax increases in Mexico and challenges to sales volume for 2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2024, ARCA biopharma has already paid €17.40 in dividends. The last payout was in August 2024.

Financials

In the last quarter, ARCA biopharma had revenue of €0 and net profit of -€44.11m

(EUR)	September 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-44.11m	70.98%
EBITDA	-54.86m	112.76%

Fundamentals

Metric	Value
Market capitalization	€31.4m
Number of shares	1.21m
52-week high/low	€48.58 - €2.03
Dividends	No
Beta	0.90
P/E ratio	-44.47
PEG ratio	-1.82
P/B ratio	6.41
P/S ratio	0.00

Company profile

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Name	ARCA biopharma
CEO	Thomas A. Keuer
Headquarters	Westminster, co USA
Website	arcabio.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	08/08/1997
Employees	3